Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $280,300.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of Akero Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00. Following the transaction, the chief operating officer now directly owns 218,083 shares in the company, valued at $6,112,866.49. This trade represents a 4.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jonathan Young also recently made the following trade(s):

• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.13, for a total value of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.57, for a total value of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.15, for a total value of $1,206,000.00.

Akero Therapeutics Stock Down 2.1 %

Shares of NASDAQ AKRO traded down $0.60 during mid-day trading on Monday, hitting $27.64. The company had a trading volume of 648,298 shares, compared to its average volume of 829,566. Akero Therapeutics, Inc. has a 1-year low of $15.32 and a 1-year high of $37.00. The company has a market capitalization of $1.93 billion, a PE ratio of -7.37 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The business’s 50-day simple moving average is $30.54 and its 200 day simple moving average is $27.91.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, analysts predict that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after purchasing an additional 446 shares in the last quarter. Eastern Bank acquired a new position in shares of Akero Therapeutics during the third quarter worth $100,000. Summit Financial Wealth Advisors LLC purchased a new position in Akero Therapeutics in the third quarter valued at $205,000. Victory Capital Management Inc. acquired a new position in shares of Akero Therapeutics during the 3rd quarter worth about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Akero Therapeutics in the 3rd quarter valued at about $265,000.

Analyst Ratings Changes

A number of research firms have commented on AKRO. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research report on Monday, November 18th. Citigroup initiated coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.83.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.